Sector News

DS Biopharma spins out Afimmune

August 24, 2016
Life sciences

Dublin, Ireland-based lipid science group DS Biopharma has launched a spin-out group focused solely on fibrotic conditions such as non-alcoholic steatohepatitis (NASH) and pulmonary disorders such as chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF).

The new company, called Afimmune, will continue explore the potential of DS102, a novel, anti-fibrotic compound, in NASH as well as certain pulmonary disorders, and also has a number of other compounds in preclinical development.

Afimmune plans to start a Phase IIa study with DS102 in NASH patients later this year, as well as a Phase IIa clinical trial in COPD patients following positive preclinical data.

DS Biopharma will concentrate its efforts on the development of DS107, an anti-inflammatory compound for atopic dermatitis and pruritus, and DS109 for other inflammatory skin disorders such as acne.

“By spinning out DS102 into a new company, DS Biopharma can direct its full attention to developing products for inflammatory skin conditions whereas Afimmune will focus on fibrotic conditions and pulmonary disorders,” noted Dr John Climax, the firm’s executive chairman.

By Selina McKee

Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.